139 related articles for article (PubMed ID: 16927109)
1. [Adjuvant therapy of melanoma. From non-specific immune stimulants into the future].
Hauschild A; Kleeberg UR
Hautarzt; 2006 Sep; 57(9):764-72. PubMed ID: 16927109
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of malignant melanoma. First-, second- and pathogenesis-oriented third-line therapies].
Rass K; Tadler D; Tilgen W
Hautarzt; 2006 Sep; 57(9):773-84. PubMed ID: 16924435
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
[TBL] [Abstract][Full Text] [Related]
4. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
Kirkwood JM; Moschos S; Wang W
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2331s-2336s. PubMed ID: 16609054
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant application of interferons.
el Kassas H; Kirkwood JM
Semin Oncol; 1996 Dec; 23(6):737-43. PubMed ID: 8970596
[No Abstract] [Full Text] [Related]
6. The systemic treatment of advanced cutaneous melanoma.
Logan TF
Facial Plast Surg Clin North Am; 2003 Feb; 11(1):75-85. PubMed ID: 15062290
[No Abstract] [Full Text] [Related]
7. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy for malignant melanoma.
Stoutenburg JP; Schrope B; Kaufman HL
Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
[TBL] [Abstract][Full Text] [Related]
9. [Adjuvant systemic treatment of melanoma].
Kähler KC; Egberts F; Hauschild A; Mohr P
Hautarzt; 2011 Jun; 62(6):414, 416-22. PubMed ID: 21656113
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with WT-1 (Wilms' tumor gene-1) peptide and BCG-CWS in melanoma.
Nishioka M; Tanemura A; Nishida S; Nakano A; Tsuboi A; Oji Y; Oka Y; Azuma I; Sugiyama H; Katayama I
Eur J Dermatol; 2012; 22(2):258-9. PubMed ID: 22240317
[No Abstract] [Full Text] [Related]
11. Vaccination and melanoma risk.
Pfahlberg A; Botev IN; Kölmel KF; Gefeller O
Int J Cancer; 2002 Nov; 102(1):96-7. PubMed ID: 12353240
[No Abstract] [Full Text] [Related]
12. Use of adjuvant therapy in cutaneous melanoma.
Sondak VK
Expert Rev Anticancer Ther; 2001 Oct; 1(3):421-6. PubMed ID: 12113108
[TBL] [Abstract][Full Text] [Related]
13. Who benefits most from adjuvant interferon treatment for melanoma?
Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E
Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous melanoma: available therapy for metastatic disease.
Tarhini AA; Agarwala SS
Dermatol Ther; 2006; 19(1):19-25. PubMed ID: 16405566
[TBL] [Abstract][Full Text] [Related]
15. A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma.
Wages NA; Slingluff CL; Petroni GR
Contemp Clin Trials; 2015 Mar; 41():172-9. PubMed ID: 25638752
[TBL] [Abstract][Full Text] [Related]
16. Treatment of melanoma and nonmelanoma skin cancer.
Rass K; Tilgen W
Adv Exp Med Biol; 2008; 624():296-318. PubMed ID: 18348465
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy of melanoma.
Spitler LE
Oncology (Williston Park); 2002 Jan; 16(1 Suppl 1):40-8. PubMed ID: 11829281
[TBL] [Abstract][Full Text] [Related]
18. Current therapy of cutaneous melanoma.
Mays SR; Nelson BR
Cutis; 1999 May; 63(5):293-8. PubMed ID: 10349545
[TBL] [Abstract][Full Text] [Related]
19. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
